Clinical Trial Details


Research Study Summary

A Phase 3 Study Comparing 2 Doses of study drug vs. Placebo for Treatment of Rheumatoid Arthritis


This Phase 3 study is intended to provide evidnece of the efficacy and safety of study drug when dosed twice a day in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of study drug in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.

Patient Inclusion Criteria:

  • The patient has a diagnosis of RA.
  • The patient has active disease at the onset of the study.
  • Patient had an inadequate response to current RA medicine.

Patient Exclusion Criteria:

  • Patient does not have cancer.
  • Patient does not have a history of infection requiring hospitalization within the 6 months prior to the first dose of study drug.

To Learn more

CW ID: 159063
Date Last Changed: July 24, 2013

Clinical Trial Snapshot

Both Male and Female
Overall Status
Facility Type


Suzi DeFiesta, Research Administrator
CSI Research Inc
11379 Southbridge Parkway, Suite B
Alpharetta, GA 30022
Phone: 770-667-0220
Fax: 770-667-0227

View Map

Research Center Information:

CSI Research Inc

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.